Antibody stability : A key to performance - Analysis, influences and improvement
Copyright © 2020 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved..
An antibody's stability greatly influences its performance (i.e. its specificity and affinity). Thus, stability is a major issue for researchers and manufacturers, especially with the increasing use of antibodies in therapeutics, diagnostics and rapid analytical platforms. Here we review antibody stability under five headings: (i) measurement techniques; (ii) stability issues in expression and production (expression, proteolysis, aggregation); (iii) effects of antibody format and engineering on stability and (iv) formulation, drying and storage conditions. We consider more than 100 sources, including patents, and conclude with (v) recommendations to promote antibody stability.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:177 |
|---|---|
| Enthalten in: |
Biochimie - 177(2020) vom: 10. Okt., Seite 213-225 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Hui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 27.05.2021 Date Revised 27.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biochi.2020.08.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314644385 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314644385 | ||
| 003 | DE-627 | ||
| 005 | 20231225153156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biochi.2020.08.019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1048.xml |
| 035 | |a (DE-627)NLM314644385 | ||
| 035 | |a (NLM)32891698 | ||
| 035 | |a (PII)S0300-9084(20)30205-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Hui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody stability |b A key to performance - Analysis, influences and improvement |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.05.2021 | ||
| 500 | |a Date Revised 27.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved. | ||
| 520 | |a An antibody's stability greatly influences its performance (i.e. its specificity and affinity). Thus, stability is a major issue for researchers and manufacturers, especially with the increasing use of antibodies in therapeutics, diagnostics and rapid analytical platforms. Here we review antibody stability under five headings: (i) measurement techniques; (ii) stability issues in expression and production (expression, proteolysis, aggregation); (iii) effects of antibody format and engineering on stability and (iv) formulation, drying and storage conditions. We consider more than 100 sources, including patents, and conclude with (v) recommendations to promote antibody stability | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antibody engineering | |
| 650 | 4 | |a Antibody stability | |
| 650 | 4 | |a Formulation | |
| 650 | 4 | |a Protein expression | |
| 650 | 4 | |a Protein stability measurement | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 700 | 1 | |a Ó'Fágáin, Ciarán |e verfasserin |4 aut | |
| 700 | 1 | |a O'Kennedy, Richard |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochimie |d 1971 |g 177(2020) vom: 10. Okt., Seite 213-225 |w (DE-627)NLM000014419 |x 1638-6183 |7 nnns |
| 773 | 1 | 8 | |g volume:177 |g year:2020 |g day:10 |g month:10 |g pages:213-225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biochi.2020.08.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 177 |j 2020 |b 10 |c 10 |h 213-225 | ||